236. TNF-related Apoptosis-inducing Ligand (TRAIL) Protein as a Marker for Disease Severity in Patients With Acute Infection
Session: Poster Abstract Session: Diagnostics: Use of Biomarkers
Thursday, October 27, 2016
Room: Poster Hall
Posters
  • IDweek 2016_poster-Final.pdf (924.9 kB)
  • Background:

    TRAIL is a member of the tumor necrosis factor family implicated in programmed cell death. We recently demonstrated that TRAIL can serve as a useful biomarker for distinguishing between bacterial and viral infections when computationally combined with CRP and IP-10 (Oved et al. 2015). Here we report that low TRAIL concentration in the blood is significantly correlated with poor patient prognosis and higher disease severity.

    Methods:

    We studied 765 hospitalized and emergency department patients with acute infection and controls with no apparent infection, prospectively recruited between 2009 and 2013. Patient etiology (319 bacterial, 334 viral, and 112 control) was determined by a panel of three independent experts based on comprehensive clinical and laboratory assessment that included two multiplex-PCR panels applied to nasal swabs (Seeplex-RV15/PB6). Serum TRAIL levels were measured using commercially available ELISA kits (MeMed, IL).

    Results:

    TRAIL serum levels were significantly decreased in bacterial patients and increased in viral patients as compared to controls (average±SD [pg/ml]: bacterial 45±33; viral 145±110; controls 77±32, P<10-15). Further analysis of the infectious patients group (n=653), revealed that patients with TRAIL levels lower than 25 pg/ml (n=93), were characterized by more severe disease outcome compared to patients with higher TRAIL levels (n=560) including longer hospitalization duration (7.5±11.3 vs 1.9±2.2 days, P<10-5), and need for mechanical ventilation and ICU admission (6/93 vs 0/560, P<10-5). Severe clinical syndromes such as bacteremia and septic shock were also statistically enriched in the low TRAIL sub-group (64% (7/11) of all bacteremia cases P<10-3, and 100% (7/7) of all septic shock cases, P<10-6).

    Conclusion:

    TRAIL serum levels lower than 25 pg/ml were correlated with longer hospitalization duration, ICU admission and severe clinical syndromes. These results suggest that TRAIL has the potential to serve as a marker for disease severity. Timely measurement of TRAIL serum levels might therefore enable a more accurate risk stratification, treatment optimization, and potentially better patient outcome.

    Kfir Oved, PhD1, Asi Cohen, PhD1, Olga Boico, PhD1, Roy Navon, MSc1, Tom Friedman, MD1,2, Liat Etshtein, MD1, Ellen Bamberger, MD1,3,4, Ester Pri-or, MPH1, Tanya Gottlieb, PhD1, Meital Paz, B.Sc.1, Isaac Srugo, MD3,4, Irina Chistyakov, MD3,4, Adi Klein, MD5, Israel Potasman, MD, FIDSA6 and Eran Eden, PhD1, (1)MeMed Diagnostics, Tirat Carmel, Israel, (2)Rambam Medical Center, Haifa, Israel, (3)Department of Pediatrics, Bnai Zion Medical Center, Haifa, Israel, (4)Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel, (5)Department of Pediatrics, Hillel Yaffe Medical Center, Hadera, Israel, (6)Infectious Diseases, Bnai Zion Med. Ctr., Haifa, Israel

    Disclosures:

    K. Oved, MeMed Diagnostics: Board Member , Employee and Shareholder , Salary

    A. Cohen, MeMed Diagnostics: Employee , Salary

    O. Boico, MeMed Diagnostics: Employee , Salary

    R. Navon, MeMed Diagnostics: Employee , Salary

    T. Friedman, MeMed Diagnostics: Employee , Salary

    L. Etshtein, MeMed Diagnostics: Employee , Salary

    E. Bamberger, MeMed Diagnostics: Employee , Salary

    E. Pri-or, MeMed Diagnostics: Employee , Salary

    T. Gottlieb, MeMed Diagnostics: Employee , Salary

    M. Paz, MeMed Diagnostics: Employee , Salary

    I. Srugo, None

    I. Chistyakov, MeMed Diagnostics: Consultant , Consulting fee

    A. Klein, None

    I. Potasman, MeMed Diagnostics: Shareholder , Stock options

    E. Eden, MeMed Diagnostics: Board Member , Employee and Shareholder , Salary

    << Previous Abstract | Next Abstract

    Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.